This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
by Kinjel Shah
FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.
Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication
by Zacks Equity Research
Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).
Lilly Gains as Verzenio Meets Early Breast Cancer Study Goal
by Zacks Equity Research
Lilly's (LLY) phase III study on Verzenio in HR+, HER2- early breast cancer met its primary endpoint of invasive disease-free survival.
Bayer Initiates a Phase III Study in Heart Failure Patients
by Zacks Equity Research
Bayer (BAYRY) initiates a phase III study to evaluate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction.
FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus
by Kinjel Shah
The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.
Novartis' (NVS) Beovu Gets FDA Approval for Label Update
by Zacks Equity Research
Novartis' (NVS) ophthalmology drug, Beovu, gets update for safety information regarding retinal vasculitis and retinal vascular occlusion.
The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International
Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD
by Zacks Equity Research
Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.
Bayer (BAYRY) Submits Applications for Heart Failure Drug
by Zacks Equity Research
Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.
Alnylam Reports Positive Phase III Results on Lumasarin
by Zacks Equity Research
Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.
Here's Why You Should Retain Genpact (G) in Your Portfolio
by Zacks Equity Research
Genpact (G) is currently benefiting from a strong customer base and accretive acquisitions.
Top Stock Reports for Mastercard, Novartis & Boeing
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Novartis (NVS) and Boeing Company (BA).
Novartis' Asthma Treatment Meets Primary Endpoint in Phase III
by Zacks Equity Research
Novartis (NVS) announces positive results from a late-stage study on Enerzair Breezhaler in patients with asthma.
Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.
Novartis (NVS) Announces Positive Data From Cosentyx Study
by Zacks Equity Research
Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.
Novartis' sBLA for Ofatumumab Gets Extended Review From FDA
by Zacks Equity Research
The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.
AbbVie Seeks US and EU Nods for Rinvoq for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) files applications to the FDA and the EMA seeking approval for a new indication of Rinvoq, active psoriatic arthritis. The drug is already marketed to treat rheumatoid arthritis.
Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.
Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III PALLAS study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer.
PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment
by Zacks.com
PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.
Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA
by Zacks Equity Research
Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.
Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA
by Zacks Equity Research
Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.
Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock
by Zacks Equity Research
The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.
Acceleron (XLRN) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acceleron (XLRN) posts a wider-than-expected Q1 loss due to increased operating expenses. The company misses on revenues as well.
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.